Targeting the PD-1/PD-L1 axis in the treatment of lung cancer

Agent	Clinical Setting	Comparison	Clinicaltrials. gov Identifier
Nivolumab
	First line, any NSCLC histology	Vs platinum doublet (physician’s choice)	NCT02041533
	First line, any NSCLC histology	4 arms: nivolumab vs nivolumab/ipilimumab vs nivolumab/chemotherapy vs chemotherapy (platinum based doublet, physician’s choice)	NCT02477826
	Second line NSCLC after platinum based doublet	Vs docetaxel	NCT02613507
	Adjuvant treatment NSCLC after resection and chemotherapy	Vs placebo	NCT02595944
	Relapsed SCLC	Vs topotecan or amrubicin	NCT02481830
	Extensive SCLC, maintenance after first line treatment	nivolumab vs nivolumab/ipilimumab vs placebo	NCT02538666
Pembrolizumab
	Adjuvant treatment NSCLC after resection with or without chemotherapy	Vs placebo	NCT02504372
	First line, any NSCLC histology, PD-L1 positive	Vs platinum based doublet chemotherapy	NCT02220894
	First line, any NSCLC histology	Vs platinum based doublet chemotherapy	NCT02142738
	First line, any NSCLC histology	Platinum/pemetrexed, with or without pembrolizumab	NCT02578680
Atezolizumab
	First line, non-squamous NSCLC	Platinum/pemetrexed, with or without atezolizumab	NCT02657434
	First line, squamous NSCLC	Carboplatin/taxane with or without atezolizumab	NCT02367794
	First line, PD-L1 positive squamous NSCLC	Vs platinum/gemcitabine	NCT02409355
	First line, PD-L1 positive non-squamous NSCLC	Vs platinum/pemetrexed	NCT02409342
	First line, non-squamous NSCLC	3 arms: paclitaxel/carboplatin/atezolizumab vs paclitaxel/carboplatin/bevacizumab vs paclitaxel/ carboplatin/bevacizumab/atezolizumab	NCT02366143
	First line, non-squamous NSCLC	Carboplatin/nab-paclitaxel with or without atezolizumab	NCT02367781
	Second line NSCLC after platinum based doublet	Vs docetaxel	NCT02008227
	Adjuvant treatment NSCLC after resection and chemotherapy	Vs placebo	NCT02486718
Durvalumab
	First line, any NSCLC histology	Durvalumab vs durvalumab/tremelimumab vs platinum based doublet	NCT02453282
	Stage III NSCLC following chemoradiotherapy	Vs placebo	NCT02125461
	Adjuvant treatment NSCLC after resection and chemotherapy	Vs placebo	NCT02273375
	Third line NSCLC	Durvalumab vs durvalumab/tremelimumab vs monotherapy (gemcitabine, vinorelbine or erlotinib)	NCT02352948

Published trials in full form of PD-1 inhibitors.

Agent	Reference	Phase	N	Comparison/Setting	Response Rate	PFS (months)	OS (months)	Comments
Nivolumab
	Gettinger et al [15]	1	129	N/A / Heavily pretreated	17%	2.3	9.9
	Rizvi et al [16]	2	117	N/A / Heavily pretreated	14,5%	1.9	8.2
	Brahmer et al [17]	3	272	Docetaxel / 2nd line squamous	20% vs 8% (P=0.008)	3.5 vs 2.8 (P<0.001)	9.2 vs 6.0 (P<0.001)
	Borghaei et al [18]	3	587	Docetaxel / 2nd line non-squamous	19% vs 12% (P=0.02)	2.3 vs 4.2 (NS)	12.1 vs 9.4 (P=0.002)
Pembrolizumab	Garon et al [27]	1	495	N/A / Heavily pretreated	19,4%	3.7	12.0
	Herbst et al [29]	2/3	1043	Docetaxel / 2nd line PD-L1≥1%	18% vs 9% (P=0.0002)	4.0 vs 4.0 (NS)	12.7 vs 8.5 (P<0.0001)	10 mg/kg arm vs docetaxel
	Herbst et al [29]	2/3	1043	Docetaxel / 2nd line PD-L1≥1%	18% vs 9% (P=0.0005)	3.9 vs 4.0 (NS)	10.4 vs 8.5 (P=0.0008)	2 mg/kg arm vs docetaxel

eISSN:: 1792-362X
Lingua:: Inglese

Frequenza di pubblicazione:: 4 volte all'anno
Argomenti della rivista:: Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology

Feed RSS della rivista

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer

Article Category: Research Article

Pubblicato online: 17 set 2016

Pagine: 17 - 27

Ricevuto: 16 feb 2016

Accettato: 16 feb 2016

DOI: https://doi.org/10.1515/fco-2015-0021

Parole chiaveNSCLC, PD-1, PD-L1, Nivolumab, Pembrolizumab

© 2016

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ongoing phase III trials of anti-PD-1/PD-L1 agents and combinations in Non-Small Cell Lung Cancer and Small Cell Lung Cancer.

Published trials in full form of PD-1 inhibitors.

Parole chiave
NSCLC, PD-1, PD-L1, Nivolumab, Pembrolizumab